|Dr. Pavan Cheruvu M.D.||CEO & Director||510.96k||N/A||1982|
|Dr. Gregory M. Weinhoff||Principal Financial & Accounting Officer||544.08k||N/A||1971|
|Dr. David T. Hung M.D.||Scientific Advisor of Group||3.47M||N/A||1958|
|Dr. Fraser Wright||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Tricia Truehart||Head of Investor Relations||N/A||N/A||N/A|
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Axovant Gene Therapies Ltd.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 9.